NIPH Clinical Trials Search

UMIN ID: UMIN000002087

Registered date:17/06/2009

Yamagata Clinical Helicobacter pylori study group

Basic Information

Recruitment status Complete: follow-up complete
Health condition(s) or Problem(s) studiedpeptic ulcer
Date of first enrollment2000/11/01
Target sample size4000
Countries of recruitmentJapan
Study typeInterventional
Intervention(s)H. pylori eradication therapy consisted of lansoprazole 30 mg or omeprazole 20 mg, plus amoxicillin 750 mg and clarithromycin 200 or 400 mg all twice daily for 7 days. Conventional antacid therapy consisted of antacids such as proton-pump inhibitors (PPIs) and histamine-H2 blockers for 6 or 8 weeks.


Primary OutcomeIncident rate ratio (IRR) of gastric cancer between patients receiving and not receiving H. pylori eradication therapy until end of 2007.
Secondary OutcomeThe accumulated incidences of gastric cancer in patients with successful and unsuccessful H. pylori eradication

Key inclusion & exclusion criteria

Age minimum12years-old
Age maximumNot applicable
GenderMale and Female
Include criteria
Exclude criteriaPatients with a history of gastric cancer and those in whom endoscopy or biopsy at the time of registration revealed gastric cancer were excluded from the study.

Related Information


public contact
Name Katsuhiro Mabe
Address Japan
Affiliation KKR Sapporo Medical Center Gastroenterology
scientific contact
Name Katsuhiro Mabe
Address Hiragishi 1-6,Toyohira-ku,Sapporo Japan
Affiliation KKR Sapporo Medical Center Gastroenterology